LOGIN  |  REGISTER
Chimerix

Auna Announces Reporting Dates for Second Quarter 2024 Financial Results

July 30, 2024 | Last Trade: US$6.83 0.17 2.55

LUXEMBOURG / Jul 30, 2024 / Business Wire / Auna S.A. (NYSE: AUNA) (“Auna” or “the Company”), a leading Latin American healthcare services and plan provider with operations in Mexico, Peru and Colombia, announced today the reporting dates for its Second Quarter 2024 financial results.

Earnings Release

Wednesday, August 21, 2024

Time: After Market Close

Conference Call

Wednesday, August 21, 2024

Time: 5:00 p.m. ET

Quiet Period

Friday, August 2 through Wednesday, August 21, 2024

To participate, please dial

+1 888 596 4144 (Toll-Free)

+1 646 968 2525 (International)

Entry Passcode: 3884034

Webcast: click here

About Auna

Auna is a Latin American healthcare company with operations in Mexico, Peru and Colombia, prioritizing prevention and concentrating on high complexity diseases that contribute the most to healthcare expenditures. Our mission is to transform healthcare by providing access to a highly integrated healthcare offering in the underpenetrated markets of Spanish Speaking Americas. Founded in 1989, Auna has built one of Latin America’s largest modern healthcare platforms that consists of a horizontally integrated network of healthcare facilities and a vertically integrated portfolio of oncological plans and selected general healthcare plans. As of March 31, 2024, Auna’s network included 31 healthcare network facilities, consisting of hospitals, outpatient, prevention and wellness facilities with a total of 2,308 beds, and 1.2 million healthcare plans.

For more information visit www.aunainvestors.com

Viking Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB